• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Denali Capital Acquisition Corp.

    12/26/24 10:54:14 AM ET
    $DECA
    Blank Checks
    Finance
    Get the next $DECA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Denali Capital Acquisition Corp.

    (Name of Issuer)


    Class A ordinary shares, par value $0.0001 per share

    (Title of Class of Securities)


    G6256B106

    (CUSIP Number)


    12/16/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G6256B106


    1Names of Reporting Persons

    TD SECURITIES (USA) LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    30,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    30,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    30,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.4 %
    12Type of Reporting Person (See Instructions)

    BD


    SCHEDULE 13G

    CUSIP No.
    G6256B106


    1Names of Reporting Persons

    Cowen Financial Products LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    50,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    50,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    50,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    G6256B106


    1Names of Reporting Persons

    TD GROUP US HOLDINGS LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    G6256B106


    1Names of Reporting Persons

    TORONTO DOMINION BANK
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    BK


    SCHEDULE 13G

    CUSIP No.
    G6256B106


    1Names of Reporting Persons

    TORONTO DOMINION HOLDINGS USA INC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Denali Capital Acquisition Corp.
    (b)Address of issuer's principal executive offices:

    437 Madison Avenue 27th Floor New York, NEW YORK 10022
    Item 2. 
    (a)Name of person filing:

    TD SECURITIES (USA) LLC Cowen Financial Products LLC TD GROUP US HOLDINGS LLC TORONTO DOMINION BANK TORONTO DOMINION HOLDINGS USA INC
    (b)Address or principal business office or, if none, residence:

    ONE VANDERBILT AVENUE NEW YORK, New York 10017 The address of TD Securities (USA) LLC's ("TDS") principal office, Cowen Financial Products LLC's ("CFP") principal office, and Toronto Dominion Holdings (U.S.A.), Inc.'s ("TDH") principal office is 1 Vanderbilt Avenue, New York, New York 10017. The address of TD Group US Holdings LLC's ("TD GUS") principal office is 251 Little Falls Drive, Wellington, Delaware 19808. The address of Toronto Dominion Bank's ("TD Bank") principal office is Toronto-Dominion Centre, 66 Wellington Street West, 12th Floor, TD Tower, Toronto, Ontario, Canada M5K 1A2.
    (c)Citizenship:

    TD SECURITIES (USA) LLC - DELAWARE Cowen Financial Products LLC - DELAWARE TD GROUP US HOLDINGS LLC - DELAWARE TORONTO DOMINION BANK - CANADA (FEDERAL LEVEL) TORONTO DOMINION HOLDINGS USA INC - DELAWARE
    (d)Title of class of securities:

    Class A ordinary shares, par value $0.0001 per share
    (e)CUSIP No.:

    G6256B106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    80,000 TDS has the sole power to vote or direct the vote and the sole power to dispose or direct the disposition of 30,000 shares and CFP has the sole power to vote or direct the vote and the sole power to dispose or direct the disposition of 50,000 shares. This schedule is jointly filed by TDS, CFP, TDH, TD GUS and TD Bank. TDH is the sole owner of TDS and a sole, indirect owner of CFP. TD GUS is the sole owner of TDH. TD Bank is the sole owner of TD GUS. TD Bank, TDH, and TD GUS may be deemed to hold an indirect interest in the shares reported herein by virtue of their ownership of TDS and indirect ownership of CFP. Each of TDH, TD GUS and TD Bank disclaims ownership of the shares reported herein except to the extent of its pecuniary interest therein. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) of the US Securities Exchange Act of 1934 or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.
    (b)Percent of class:

    5.4  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    TD SECURITIES (USA) LLC - 30000 Cowen Financial Products LLC - 50000 TD GROUP US HOLDINGS LLC - 0 TORONTO DOMINION BANK - 0 TORONTO DOMINION HOLDINGS USA INC - 0

     (ii) Shared power to vote or to direct the vote:

    TD SECURITIES (USA) LLC - 0 Cowen Financial Products LLC - 0 TD GROUP US HOLDINGS LLC - 0 TORONTO DOMINION BANK - 0 TORONTO DOMINION HOLDINGS USA INC - 0

     (iii) Sole power to dispose or to direct the disposition of:

    TD SECURITIES (USA) LLC - 30000 Cowen Financial Products LLC - 50000 TD GROUP US HOLDINGS LLC - 0 TORONTO DOMINION BANK - 0 TORONTO DOMINION HOLDINGS USA INC - 0

     (iv) Shared power to dispose or to direct the disposition of:

    TD SECURITIES (USA) LLC - 0 Cowen Financial Products LLC - 0 TD GROUP US HOLDINGS LLC - 0 TORONTO DOMINION BANK - 0 TORONTO DOMINION HOLDINGS USA INC - 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    TD SECURITIES (USA) LLC
     
    Signature:Christina Petrou
    Name/Title:Vice President & Chief Operating Officer
    Date:12/23/2024
     
    Cowen Financial Products LLC
     
    Signature:John Holmes
    Name/Title:Chief Operating Officer
    Date:12/23/2024
     
    TD GROUP US HOLDINGS LLC
     
    Signature:Ryan A. Barry
    Name/Title:Head of Finance and Accounting
    Date:12/23/2024
     
    TORONTO DOMINION BANK
     
    Signature:Christina Petrou
    Name/Title:Vice President & Chief Operating Officer
    Date:12/23/2024
     
    TORONTO DOMINION HOLDINGS USA INC
     
    Signature:Christina Petrou
    Name/Title:Vice President & Chief Operating Officer
    Date:12/23/2024
    Exhibit Information

    EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the ordinary shares of Denali Capital Acquisition Corp. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Dated: December 23, 2024 TD Securities (USA) LLC By: /s/ Christina Petrou Title: Vice President & Chief Operating Officer Cowen Financial Products LLC By: /s/John Holmes Title: Chief Operating Officer TORONTO DOMINION HOLDINGS (U.S.A.), INC. By: /s/ Christina Petrou Title: Vice President & Chief Operating Officer TD GROUP US HOLDINGS LLC By: /s/ Ryan A. Barry Title: Head of Finance and Accounting THE TORONTO-DOMINION BANK By: /s/ Christina Petrou Title: Vice President & Chief Operating Officer

    Get the next $DECA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DECA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DECA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Denali Capital Global Investments Llc

    4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)

    9/16/24 10:05:57 AM ET
    $DECA
    Blank Checks
    Finance

    SEC Form 4 filed by Large owner Xu Jiandong

    4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)

    9/16/24 10:01:42 AM ET
    $DECA
    Blank Checks
    Finance

    $DECA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

    NEW YORK, NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $874.78 to fund the one-month extension from June 11, 2025 to July 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a busines

    6/11/25 8:30:00 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

    NEW YORK, NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) --  Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $874.78 to fund the one-month extension from May 11, 2025 to June 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business

    5/9/25 4:00:00 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination

    NEW YORK, NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that on April 11, 2025, the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the "Articles") to extend the date by which the Company must consummate an initial business combination from April 11, 2025 to December 11, 2025 by electing to extend the date to consummate an initial business combination on a monthly basis for up to eight times by an additional one month each time (the "Extension"). The Company also announced today that on April 11, 2025, the Company deposit

    4/14/25 4:35:00 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DECA
    SEC Filings

    View All

    Denali Capital Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

    4/22/25 5:10:19 PM ET
    $DECA
    Blank Checks
    Finance

    Amendment: SEC Form S-4/A filed by Denali Capital Acquisition Corp.

    S-4/A - Denali Capital Acquisition Corp. (0001913577) (Filer)

    4/21/25 5:17:32 PM ET
    $DECA
    Blank Checks
    Finance

    Denali Capital Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

    4/15/25 9:20:12 PM ET
    $DECA
    Blank Checks
    Finance

    $DECA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

    SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

    12/6/24 4:17:05 PM ET
    $DECA
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

    SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

    11/14/24 5:49:50 PM ET
    $DECA
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

    SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

    11/14/24 2:35:09 PM ET
    $DECA
    Blank Checks
    Finance

    $DECA
    Financials

    Live finance-specific insights

    View All

    Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

    As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator

    11/6/24 12:24:36 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

    Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with

    10/28/24 6:00:00 AM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

    Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))).Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scile

    10/16/24 4:00:00 AM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care